Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Preclinical Research on Osteoarthritis and Osteoporosis
share announcement

Preclinical Research on Osteoarthritis and Osteoporosis

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 2001

Special Issue Editors

Dr. Tien-Ching Lee

E-Mail Website
Guest Editor
1. Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
2. College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3. Orthopedic Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan
Interests: osteoporosis; bone healing; orthopedic trauma; hand surgery
Dr. Chung-Hwan Chen

E-Mail Website
Guest Editor
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
Interests: osteoporosis; bone and cartilage; EGCG catechin; osteoarthritis; stem cell; development/degeneration of spine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Osteoporosis (OP) and osteoarthritis (OA) are both common diseases worldwide with increasing incidence due to population aging and cause function loss and disability, especially among the elderly. They result in significant personal and social burdens due to their high disability rates, medical costs, and increased mortality. The etiologies of these chronic diseases are multifactorial. Even though these heterogeneous conditions bring about a challenge for the development of effective treatment for OP and OA, there are many emerging treatments that promise to bring benefits for OP and OA management in the future. However, preclinical research is essential to provide detailed information on dosing and toxicity levels. After preclinical testing, researchers must review their findings and decide whether the potential drug or intervention should be tested in humans.

We hope that this Special Issue will provide a comprehensive and multisystem approach to explore the pathophysiological mechanism of OP and OA and to guide the development of novel therapeutic strategies of OP and OA.

Dr. Tien-Ching Lee
Dr. Chung-Hwan Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • osteoporosis
  • osteoarthritis
  • preclinical study
  • in vitro
  • in vivo
  • antiosteoporosis
  • DMOADs
  • anabolic
  • antiresorptive

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 4625 KiB  
Article
In Vitro Screening Studies on Eight Commercial Essential Oils-Derived Compounds to Identify Promising Natural Agents for the Prevention of Osteoporosis
by Marta Trzaskowska, Vladyslav Vivcharenko, Paulina Kazimierczak, Agata Wolczyk and Agata Przekora
Biomedicines 2023, 11(4), 1095; https://doi.org/10.3390/biomedicines11041095 - 4 Apr 2023
Cited by 2 | Viewed by 1722
Abstract
Over the years, essential oils (EOs) and their compounds have gained growing interest due to their anti-inflammatory, antimicrobial, antioxidant, and immunomodulatory properties. The aim of this study was to evaluate the effect of eight commercially available EO-derived compounds ((R)-(+)-limonene, (S)-(−)-limonene, sabinene, carvacrol, thymol, [...] Read more.
Over the years, essential oils (EOs) and their compounds have gained growing interest due to their anti-inflammatory, antimicrobial, antioxidant, and immunomodulatory properties. The aim of this study was to evaluate the effect of eight commercially available EO-derived compounds ((R)-(+)-limonene, (S)-(−)-limonene, sabinene, carvacrol, thymol, alpha-pinene (α-pinene), beta-pinene (β-pinene), and cinnamaldehyde) on the bone formation process in vitro to select the most promising natural agents that could potentially be used in the prevention or treatment of osteoporosis. Within this study, evaluation of cytotoxicity, cell proliferation, and osteogenic differentiation was performed with the use of mouse primary calvarial preosteoblasts (MC3T3-E1). Moreover, extracellular matrix (ECM) mineralization was determined using MC3T3-E1 cells and dog adipose tissue-derived mesenchymal stem cells (ADSCs). The two highest non-toxic concentrations of each of the compounds were selected and used for testing other activities. The conducted study showed that cinnamaldehyde, thymol, and (R)-(+)-limonene significantly stimulated cell proliferation. In the case of cinnamaldehyde, the doubling time (DT) for MC3T3-E1 cells was significantly shortened to approx. 27 h compared to the control cells (DT = 38 h). In turn, cinnamaldehyde, carvacrol, (R)-(+)-limonene, (S)-(−)-limonene, sabinene, and α-pinene exhibited positive effects on either the synthesis of bone ECM or/and mineral deposition in ECM of the cells. Based on the conducted research, it can be assumed that cinnamaldehyde and (R)-(+)-limonene are the most promising among all tested EO-derived compounds and can be selected for further detailed research in order to confirm their biomedical potential in the chemoprevention or treatment of osteoporosis since they not only accelerated the proliferation of preosteoblasts, but also significantly enhanced osteocalcin (OC) synthesis by preosteoblasts (the OC level was approx. 1100–1200 ng/mg compared to approx. 650 ng/mg in control cells) and ECM calcification of both preosteoblasts and mesenchymal stem cells. Importantly, cinnamaldehyde treatment led to a three-fold increase in the mineral deposition in ADSCs, whereas (R)-(+)-limonene caused a two-fold increase in the ECM mineralization of both MC3T3-E1 cells and ADSCs. Full article
(This article belongs to the Special Issue Preclinical Research on Osteoarthritis and Osteoporosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop